Stryker Co. (NYSE:SYK) Shares Purchased by Park Avenue Securities LLC

Park Avenue Securities LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 25.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,613 shares of the medical technology company's stock after buying an additional 2,142 shares during the quarter. Park Avenue Securities LLC's holdings in Stryker were worth $3,821,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Dale Q Rice Investment Management Ltd purchased a new stake in Stryker during the 4th quarter worth approximately $587,000. PFW Advisors LLC acquired a new stake in shares of Stryker in the fourth quarter worth approximately $1,350,000. Parnassus Investments LLC purchased a new stake in shares of Stryker during the third quarter worth approximately $762,798,000. Baltimore Washington Financial Advisors Inc. raised its stake in Stryker by 2.4% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company's stock valued at $24,089,000 after purchasing an additional 1,554 shares during the last quarter. Finally, Sivik Global Healthcare LLC lifted its holdings in Stryker by 8.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company's stock valued at $9,754,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Up 0.6 %

Shares of Stryker stock traded up $2.12 during trading hours on Friday, reaching $383.91. 1,727,106 shares of the company were exchanged, compared to its average volume of 1,369,246. The firm has a market cap of $146.35 billion, a PE ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The stock's fifty day moving average is $375.35 and its 200 day moving average is $358.48.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker's revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 EPS. As a group, equities research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's dividend payout ratio is currently 36.01%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SYK shares. Citigroup increased their target price on shares of Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. StockNews.com upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Thursday, January 9th. Royal Bank of Canada restated an "outperform" rating and set a $425.00 target price on shares of Stryker in a report on Tuesday, January 7th. Morgan Stanley upgraded Stryker from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. lifted their price objective on Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $405.80.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 5.50% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.